Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

NCT02243098 · Completed

Last updated 2026-05-28

This clinical trial is testing how the diabetes medication semaglutide affects the levels of atorvastatin and digoxin in the blood of healthy adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 31 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2014-09 · est. completion 2015-04

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02243098 ↗

Description as written by the study sponsor.

The trial is conducted in Europe. The aim of the trial is to investigate the influence of semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of single doses of atorvastatin and digoxin in healthy subjects.

Treatments tested

semaglutide Drug

Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
digoxin Drug

Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
atorvastatin Drug

Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.

Main thing measured	Area under the atorvastatin plasma concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02243098 ↗